FDA has designated Editas Medicine's EDIT-301 candidate as an orphan drug for beta-thalassemia. Preparations are underway for a Phase 1/2 EDIT-301 clinical trial of the drug, which is planned for the end of the year.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept